Liang, Weifeng
Gu, Ming https://orcid.org/0000-0001-5584-9755
Zhu, Lingxiang
Yan, Ziqi
Schenten, Dominik
Herrick, Shelby
Li, Hongmin
Samrat, Subodh Kumar
Zhu, Jiapeng https://orcid.org/0000-0002-9165-0126
Chen, Yin
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (AI139439, AI149754, AI161845, AI131669, AI140406, AI141178, AI140726)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences (ES027013, ES028889, ES025494)
U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences
U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
R. Ken and Donna Coit Endowed Chair fund in Drug Discovery
Article History
Received: 27 August 2022
Revised: 26 February 2023
Accepted: 21 March 2023
First Online: 13 April 2023
Competing interests
: The authors declare no competing interests.
: All SARS-CoV-2 related work were performed within the University of Arizona Biosafety Level 3 (BSL3) facility. Other experiments were performed in the laboratory meeting the BSL2 standard. All protocols have been approved by The Institutional Biosafety Committee (IBC) of the University of Arizona.